Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akkermansia muciniphila EB-AMDK 19
- Development stage
- Preclinical
- Lead developer
- Enterobiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Akkermansia muciniphila EB-AMDK 19** is a specific probiotic bacterial strain of the species *Akkermansia muciniphila*, isolated from the feces of healthy Koreans. EB-AMDK 19 has been evaluated primarily in preclinical research as a next-generation probiotic for its capacity to modulate immune response and gut health. Heat-killed Akkermansia muciniphila EB-AMDK 19 (referred to as AMDK19-HK) demonstrated beneficial effects in a mouse model of allergic asthma: oral administration improved allergic airway inflammation, reduced inflammatory cell infiltration, decreased Th2 cytokine expression, increased short-chain fatty acid (SCFA) production, and improved intestinal mucosal barrier function. The primary proposed mechanism involves decreasing Th2-mediated immune responses and modulating gut immune and metabolic environment. EB-AMDK 19 is not currently an approved pharmaceutical but is studied as a live biotherapeutic/probiotic agent for immune and gastrointestinal modulation[4].
- Other names
- Akkermansia muciniphila EB-AMDK 19
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Akkermansia muciniphila EB-AMDK 19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akkermansia muciniphila EB-AMDK 19.